A protein called dopamine beta-hydroxylase (DBH) plays a key role in atherosclerosis by disrupting copper metabolism in blood vessel cells, according to a 2026 research study. Scientists found that DBH levels were significantly elevated in atherosclerosis patients and in cells exposed to damaged cholesterol. When researchers reduced DBH in mice prone to heart disease, the animals developed fewer arterial plaques and showed improved cholesterol levels. While these findings suggest DBH could become a new treatment target, the research is still in early stages and has not yet been tested in human patients.
Scientists discovered that a protein called dopamine beta-hydroxylase (DBH) plays an important role in atherosclerosis, a disease where fatty buildup clogs your arteries. According to Gram Research analysis, when DBH levels get too high, it disrupts how your body handles copper, which can make heart disease worse. Researchers found that DBH was significantly elevated in patients with atherosclerosis and in lab-grown cells exposed to damaged cholesterol. When they reduced DBH in mice prone to heart disease, the animals developed fewer plaques in their arteries and had better cholesterol levels. This discovery suggests that controlling DBH could become a new way to treat or prevent atherosclerosis, though more research in humans is needed before any new treatments could be developed.
Key Statistics
A 2026 research study identified 2891 differentially expressed genes in artery tissue from atherosclerosis-prone mice, with dopamine beta-hydroxylase (DBH) being significantly upregulated compared to healthy controls.
In mice with reduced DBH levels, atherosclerotic plaque burden decreased significantly while serum lipid profiles improved and copper concentrations were restored compared to control mice.
Dopamine beta-hydroxylase expression was elevated in blood serum samples from atherosclerosis patients and in human vascular smooth muscle cells treated with oxidized LDL cholesterol, according to the 2026 study.
The Quick Take
- What they studied: How a protein called dopamine beta-hydroxylase (DBH) contributes to atherosclerosis, the buildup of plaque in arteries that can lead to heart attacks and strokes.
- Who participated: The study used mice genetically prone to atherosclerosis, human cells from blood vessel walls, and blood samples from patients with atherosclerosis. The exact number of human participants was not specified in the research.
- Key finding: DBH protein levels were significantly higher in people with atherosclerosis and in cells exposed to damaged cholesterol. When researchers reduced DBH in mice, the animals developed fewer arterial plaques and showed improved cholesterol levels.
- What it means for you: This research identifies a new target for treating heart disease, but it is still in early stages. These findings are from laboratory and animal studies, so it will take years of additional research before any new treatments based on this discovery could be tested in humans or become available.
The Research Details
Researchers used multiple approaches to understand DBH’s role in atherosclerosis. First, they analyzed genes in artery tissue from mice with atherosclerosis and found that DBH was one of 2891 genes that changed expression levels. They then confirmed that DBH levels were elevated in blood samples from atherosclerosis patients and in human cells exposed to oxidized LDL, a type of damaged cholesterol that damages blood vessels.
Next, the team investigated how DBH works. They discovered that another protein called PHOX2A acts as a master switch that turns on the DBH gene. When they reduced DBH in cells, it prevented damage and fat accumulation caused by oxidized cholesterol. Conversely, when they increased PHOX2A, it made the damage worse.
Finally, they tested their findings in mice by reducing DBH levels. These modified mice developed smaller plaques in their arteries, had better cholesterol profiles, and showed restored copper levels in their blood compared to control mice.
This research approach is important because it combines multiple methods to understand disease. By starting with genes, moving to human cells, and then testing in animals, the researchers built a strong case that DBH actually causes atherosclerosis rather than just being associated with it. Understanding the specific mechanism (how DBH affects copper metabolism) opens the door to developing targeted treatments.
The study demonstrates solid scientific methodology by using complementary approaches: gene analysis, cell culture experiments, and animal models. The findings were consistent across different systems (patient blood, human cells, and mice), which strengthens confidence in the results. However, this research has not yet been tested in human patients, so the real-world effectiveness remains unknown. The study was published in a peer-reviewed journal, meaning other experts reviewed the work before publication.
What the Results Show
The research identified DBH as a significantly upregulated protein in atherosclerosis. Among nearly 2900 genes analyzed in artery tissue from diseased mice, DBH stood out as notably elevated. This elevation was confirmed in blood samples from atherosclerosis patients and in human vascular cells exposed to oxidized LDL cholesterol.
The mechanistic findings revealed that PHOX2A, a regulatory protein, directly activates the DBH gene. When DBH was reduced in cells, it prevented the harmful effects of oxidized cholesterol, including cell death and fat accumulation. Conversely, increasing PHOX2A made these harmful effects worse, confirming the importance of this regulatory pathway.
In living mice, reducing DBH produced dramatic improvements. The modified mice developed significantly smaller atherosclerotic plaques in their arteries compared to control mice. Their blood cholesterol profiles improved, and their serum copper levels normalized. Additionally, the expression of proteins related to cuproptosis (a type of cell death linked to copper) changed in ways that appeared protective.
These results suggest that DBH acts as a key driver of atherosclerosis progression through its effects on copper metabolism, offering a new understanding of how the disease develops.
The study revealed that DBH’s effects are linked to copper metabolism and a process called cuproptosis. When DBH was reduced, proteins involved in copper handling (FDX1, LIAS, DLAT) showed altered expression patterns. This suggests that DBH doesn’t simply cause atherosclerosis directly, but rather does so by disrupting how the body manages copper, which then triggers harmful processes in blood vessel cells. This finding is significant because it identifies a specific biochemical pathway that could be targeted therapeutically.
This research adds a new piece to our understanding of atherosclerosis. Previous studies have identified many risk factors (high cholesterol, smoking, inflammation), but the specific molecular mechanisms remain incompletely understood. This work identifies DBH as a previously unrecognized player in the disease process. The connection to copper metabolism is particularly novel, as copper’s role in atherosclerosis has received less attention than other factors. The findings complement existing knowledge about how oxidized cholesterol damages blood vessels and suggest that DBH is an important link in this chain of events.
This study has important limitations to consider. First, all experiments were conducted in laboratory settings or in mice, not in human patients. Mouse models of atherosclerosis don’t perfectly replicate the human disease. Second, the study did not specify the exact number of human patients whose blood was analyzed, making it difficult to assess how representative the findings are. Third, while the research identifies DBH as important, it doesn’t prove that blocking DBH would be safe or effective as a treatment in humans. Fourth, the study focused on one specific pathway and may not account for other factors that contribute to atherosclerosis. Finally, the long-term effects of reducing DBH are unknown.
The Bottom Line
Based on this research, there are currently no new treatments or lifestyle changes to recommend for the general public. The findings are preliminary and limited to laboratory and animal studies. However, the research suggests that future treatments targeting the DBH/PHOX2A pathway may help prevent or slow atherosclerosis. People concerned about heart disease should continue following established prevention strategies: maintain a healthy diet low in saturated fats, exercise regularly, avoid smoking, manage stress, and work with their doctor to control blood pressure and cholesterol. These proven approaches remain the best current options.
This research is most relevant to cardiovascular researchers and drug developers who are seeking new targets for atherosclerosis treatment. People with a family history of heart disease or those already diagnosed with atherosclerosis may find this research interesting as it represents potential future treatment options. However, the general public should not expect immediate practical applications. Healthcare providers may eventually use this information to develop new therapies, but that process typically takes many years.
Realistic expectations require understanding the drug development timeline. This research is in the basic science stage, meaning it has identified a potential target but has not yet led to any treatments. Typically, it takes 10 to 15 years from basic research discovery to a new drug becoming available to patients. The next steps would involve testing in more animal models, then moving to human clinical trials if safety and effectiveness are demonstrated. Even if development proceeds smoothly, patients should not expect new treatments based on this discovery for at least a decade.
Frequently Asked Questions
What is dopamine beta-hydroxylase and why does it matter for heart disease?
Dopamine beta-hydroxylase (DBH) is a protein that appears to drive atherosclerosis progression by disrupting copper metabolism in blood vessel cells. A 2026 study found DBH levels were significantly higher in atherosclerosis patients, suggesting it plays an important role in how the disease develops.
Can I get tested for DBH levels to check my heart disease risk?
Currently, DBH testing is not available for clinical use. This research is still in early stages and has only been tested in laboratories and mice. Healthcare providers should continue using established risk factors like cholesterol, blood pressure, and family history to assess heart disease risk.
When will treatments targeting DBH be available for atherosclerosis?
New treatments based on this research are likely many years away. Drug development typically takes 10 to 15 years from basic research discovery to patient availability. This study is in early stages, so clinical trials in humans have not yet begun.
Should I change my diet or lifestyle based on this DBH research?
No immediate lifestyle changes are needed based on this research. Continue following proven atherosclerosis prevention strategies: eat a heart-healthy diet low in saturated fat, exercise regularly, avoid smoking, and manage stress. These established approaches remain your best current options.
How does DBH affect copper in the body and why is that important?
The study found that DBH disrupts how the body manages copper, which triggers harmful processes in blood vessel cells. This copper-related pathway may be a key mechanism driving atherosclerosis, suggesting that future treatments could target this specific process.
Want to Apply This Research?
- Users interested in heart health can track established atherosclerosis risk factors: weekly average blood pressure readings, monthly cholesterol levels (if monitored), daily exercise minutes, and weekly servings of heart-healthy foods like fish and vegetables. While this specific research doesn’t yet translate to trackable metrics, monitoring these proven risk factors remains the most evidence-based approach.
- Users can implement proven atherosclerosis prevention strategies: reduce saturated fat intake to less than 7% of daily calories, aim for 150 minutes of moderate exercise weekly, maintain a healthy weight, quit smoking if applicable, and manage stress through meditation or other relaxation techniques. These evidence-based changes address known risk factors while researchers continue developing new treatments based on discoveries like this DBH research.
- Set up quarterly check-ins to review cardiovascular health metrics with a healthcare provider. Track trends in blood pressure, cholesterol levels, weight, and exercise habits. As new research translates into clinical applications over the coming years, these baseline measurements will help assess whether new treatments provide additional benefits beyond current prevention strategies.
This article summarizes research findings and is for educational purposes only. It does not constitute medical advice. The research described is preliminary, conducted in laboratory and animal models, and has not been tested in human patients. Do not make any changes to your diet, medications, or lifestyle based on this information without consulting your healthcare provider. If you have concerns about atherosclerosis or heart disease risk, speak with a qualified medical professional who can assess your individual situation and recommend appropriate prevention or treatment strategies.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.